6 Top Gainers In Healthcare Sector (TCDA, TENX, SNSS...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Tricida Inc. (TCDA)

Gained 57.04% to close Thursday's (Mar.28) trading at $37.80.

News: The Company reported positive results from its 40-week safety extension trial, which evaluated TRC101 in chronic kidney disease patients with metabolic acidosis.

In the trial, dubbed TRCA-301E, patients treated with TRC101 showed a significant reduction in all-cause mortality and progression of chronic kidney disease versus placebo within just one year in a prespecified analysis. There was also a significant improvement from baseline in measures of physical function and physical function-related quality of life in patients treated with TRC101 compared to placebo.

Near-term Catalysts:

-- Availability of NDA-enabling 12-month registration stability data for TRC101 in mid-2019. -- Submission of NDA for TRC101, seeking approval of TRC101 through the FDA's Accelerated Approval Program, in the second half of 2019.

2. Tenax Therapeutics Inc. (TENX)

Gained 24.31% to close Thursday's trading at $2.25.

News: No news

Clinical Trial:

-- A phase II trial of Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), dubbed H-E-L-P Trial, is underway.

3. Sunesis Pharmaceuticals Inc. (SNSS)

Gained 17.82% to close Thursday's trading at $1.19.

News: No news

Clinical Trials & Near-term Catalyst:

-- A phase 1b/2 trial of Vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies is ongoing. -- An update on the ongoing Vecabrutinib trial is expected to be provided at the European Hematology Association Congress (EHA) in June 2019.

4. MYOS RENS Technology Inc. (MYOS)

MYOS is a nutrition company and the owner of Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle.

Gained 14.89% to close Thursday's trading at $1.62.

News: The Company reported financial results for the fourth quarter and fiscal year ended December 31, 2018.

Net loss for the fourth quarter of 2018 narrowed to $62 thousand from $1.01 million in the year-ago quarter. Net sales for the recent fourth quarter were $149 thousand, a decrease of 5%, compared to $157 thousand for the quarter ended December 31, 2017.

The Company expects to deliver increased sales in 2019 for its Fortetropin-based product brands.

5. Adial Pharmaceuticals Inc. (ADIL)

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder.

Gained 10.20% to close Thursday's trading at $3.24.

News: No news

Pipeline & Near-term Catalyst:

-- The Company's lead product candidate is AD04, a genetically targeted therapeutic agent, for the treatment of alcohol use disorder, and opioid use disorder.

In a phase IIb trial, AD04 showed promising results in reducing the frequency of drinking, quantity of drinking and heavy drinking in patients with alcohol use disorder.

-- Adial plans to commence the initial phase III trial of AD04 in Scandinavia and Eastern Europe during the first half of 2019.

6. Natera Inc. (NTRA)

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA.

Gained 9.74% to close Thursday's trading at $19.95.

News: No news

Recent event:

-- On March 13, the Company reported financial results for the fourth quarter and year ended December 31, 2018.

Net loss for the fourth quarter of 2018 narrowed to $31.8 million or $0.51 per share from $47.2 million or $0.90 per share for the same period in 2017. Total revenues for the recent fourth quarter increased 29% to $67.0 million from $52.0 million for the fourth quarter of 2017.

Total revenues for full-year 2018 were $257.7 million compared to $209.6 million for 2017, which represents an increase of 23%.

Looking ahead, the Company anticipates 2019 total revenues of $275 million to $302 million.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ADIL MYOS NTRA SNSS TCDA TENX